While differentiation therapy can induce a durable response in selected patient populations, e.g., the hallmark success of treating acute promyelocytic leukemia (APL) by the combination of retinoic acid and arsenic (19), the response to Wnt pathway inhibition in RNF43-mutant cancer patients may be heterogeneous. This evidence concerns the gene RNF43 and cancer.